Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Early Phase 1
Recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04265872
- Locations
- 🇺🇸
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas, Texas, United States
Continuous Glucose Monitoring of Hospitalized Patients With Diabetes
Not Applicable
Active, not recruiting
- Conditions
- Glucose, Low BloodDiabetesDiabetes MellitusGlucose, High Blood
- Interventions
- Device: Dexcom Generation 6 CGM (Dexcom Gen6) device
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT04230694
- Locations
- 🇺🇸
Baylor Scott & White Medical Center - Temple, Temple, Texas, United States
Giving a Low Carbohydrate Diet to Overcome Hypertension
Not Applicable
- Conditions
- HypertensionRisk Reduction BehaviorAfrican AmericansDiet, Carbohydrate-Restricted
- Interventions
- Other: Standard DPP-GLB dietOther: Very low carbohydrate dietBehavioral: Standard DPP-GLB program modules
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 61
- Registration Number
- NCT04230928
- Locations
- 🇺🇸
Baylor Research Institute, Dallas, Texas, United States
Safety and Efficacy of a Hepatitis B Vaccine in Immunosuppressed Patients
Phase 1
Completed
- Conditions
- Hepatitis B
- Interventions
- Biological: Heplisav-B
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 10
- Registration Number
- NCT04199715
- Locations
- 🇺🇸
Baylor Scott & White Research Institute, Dallas, Texas, United States
Cardiorenal Protective Diet
Not Applicable
Completed
- Conditions
- HypertensionChronic Kidney DiseasesCardiovascular Diseases
- Interventions
- Other: Fruits and Vegetables
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 101
- Registration Number
- NCT04117204
- Locations
- 🇺🇸
Baylor Scott & White Health and Wellness Center, Dallas, Texas, United States
Benralizumab in the Treatment of Patients With Severe Asthma With ABPA
Phase 4
Withdrawn
- Conditions
- ABPASevere AsthmaAllergic Bronchopulmonary Aspergillosis
- Interventions
- Drug: Fasenra, 30 Mg/mL Subcutaneous Solution
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2022-02-01
- Lead Sponsor
- Baylor Research Institute
- Registration Number
- NCT04108962
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
Better Me Within Trial to Improve Lifestyle Behaviors in African Americans
Not Applicable
Completed
- Conditions
- ObesityPre-diabetes
- Interventions
- Behavioral: Standard diabetes prevention programBehavioral: Faith-enhanced diabetes prevention program
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 221
- Registration Number
- NCT04082702
- Locations
- 🇺🇸
UNT Health Science Center, Fort Worth, Texas, United States
Targeted Plasticity Therapy for Posttraumatic Stress Disorder
Not Applicable
Active, not recruiting
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Device: Paired Vagus Nerve Stimulation
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2023-01-05
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 9
- Registration Number
- NCT04064762
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
TAS-102 in Extrapulmonary Neuroendocrine Carcinoma
Phase 2
- Conditions
- High-grade Extra Pulmonary Neuroendocrine Cancer
- Interventions
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 14
- Registration Number
- NCT04042714
- Locations
- 🇺🇸
Baylor Scott and White University Medical Center,, Dallas, Texas, United States
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
Phase 2
Completed
- Conditions
- Triple Negative Breast Cancer
- First Posted Date
- 2019-07-25
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 10
- Registration Number
- NCT04032080
- Locations
- 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States